Poliomyelitis

no acute pulmonary process :: Article Creator

lung rads radiopaedia :: Article Creator

neuroendocrine carcinoma lung :: Article Creator Risks And Causes Of Neuroendocrine Cancer We don't know what causes most neuroendocrine cancers. But there are some risks factors that can increase your risk of developing it. These include an inherited condition called MEN 1. Anything that can increase your risk of getting a disease is called a risk factor. Different cancers have different risk factors.­ Having one or more of these risk factors doesn't mean you will definitely get that cancer. There are 2 key groups of neuroendocrine cancer: Neuroendocrine cancer starts in different parts of your body. Where it starts is called the primary site. The possible risks and causes of NETs and NECs are different. And the risks also depend on your primary site.  Inherited conditions Most neuroendocrine cancers are not inherited . Doctors call these sporadic cancers. This means they don't kn...

esc heart failure 2023 :: Article Creator New Joint Scientific Statement On Ejection Fraction Released By Leading Heart Failure Organizations The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA of the ESC), and the Japanese Heart Failure Society (JHFS) announced today a new joint scientific statement titled The Use of Left Ventricular Ejection Fraction in the Diagnosis and Management of Heart Failure. The statement is published in the European Journal of Heart Failure. Left ventricular ejection fraction (LVEF) has long served as a central measure in assessing cardiac function and guiding heart failure (HF) management. However, limitations in its diagnostic precision, reproducibility, and relevance across the full spectrum of HF phenotypes have prompted experts to re-evaluate its role. This new statement, developed by an international panel of 21 HF experts through the Trilateral...

pulmonary hypertension left heart failure :: Article Creator Meta-analysis Reveals Pulmonary Artery Denervation As Promising Intervention For Pulmonary Hypertension Just a moment... This request seems a bit unusual, so we need to confirm that you're human. Please press and hold the button until it turns completely green. Thank you for your cooperation! Press and Hold Press and hold the button If you believe this is an error, please contact our support team. 167.71.87.121 : b122a434-c30c-4720-aae3-3880f744 Study Highlights Pulmonary Artery Denervation As A Key Intervention For Pulmonary Hypertension A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for pulmonary hypertension (PH), a condition that places patients at...

decompensated congestive cardiac failure :: Article Creator Ultrafiltration—a Highly Effective Treatment For Hypervolemic Heart Failure Cite this article Ultrafiltration—a highly effective treatment for hypervolemic heart failure. Nat Rev Cardiol 4, 296 (2007). Https://doi.Org/10.1038/ncpcardio0869 Download citation Share this article Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative Chronic Heart Failure - Heart Failure With Reduced Ejection Fraction Topic Review Introduction Chronic heart failure is a syndrome, not a specific disease, and occurs as a final common pathway in multiple disease states. The pathophysiology of chronic heart failure (HF) exists when either the left ventricle, the right ventricle, o...

pulmonary arterial hypertension treatment :: Article Creator Sotatercept May Reduce All-cause Mortality In Pulmonary Arterial Hypertension Patients, Finds Research A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial hypertension (PAH), adding sotatercept (Winrevair) to the therapy regimen helped postpone major complications. Vascular remodeling is a major pathogenic aspect of the illness that is not immediately addressed by current therapies, which instead concentrate on vasodilation. A new experimental treatment, sotatercept is intended to address this underlying condition. The fusion protein called sotatercept binds to activin A and other transforming growth factor-beta (TGF-β) superfamily ligands and neutralizes them. The vascular remodeling that takes place in PAH is linked to this route. For individuals with WHO functional class II or III pulmonary arterial hypertension, sota...